11 Best Hot Stocks to Buy According to Wall Street Analysts

4. Nektar Therapeutics (NASDAQ:NKTR)

Gain Over the Past 1 Month: 121.27%

Number of Hedge Fund Holders: 20

Average Upside Potential as of July 3: 202.91%

Nektar Therapeutics (NASDAQ:NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar Therapeutics announced positive results from its mid-stage REZOLVE-AD study for rezpegaldesleukin, which is an eczema treatment.

The Phase 2b REZOLVE-AD study evaluated rezpegaldesleukin in 393 patients with moderate-to-severe atopic dermatitis (eczema), who had not previously received biologic or JAK inhibitor therapies. Patients received 3 under-the-skin injections of the drug. After 16 weeks, patients showed improvements in symptoms as measured by the Eczema Area and Severity Index/EASI.

Unlike many existing biologic treatments that block inflammatory cytokines, rezpegaldesleukin works by boosting the body’s natural anti-inflammatory mechanisms. The safety profile of rezpegaldesleukin was generally favorable, with mild to moderate injection site reactions being the most common adverse event, occurring in 69.7% of treated patients. These reactions were mostly mild to moderate, self-resolved, and did not lead to discontinuation. Nektar Therapeutics plans to present these 16-week induction data at a scientific meeting later in 2025.

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company that discovers and develops therapies that selectively modulate the immune system to treat autoimmune disorders internationally.